Vertex Pharmaceuticals Incorporated (VRTX) Financial Statements
Vertex Pharmaceuticals Incorporated (VRTX) reported trailing twelve-month revenue of $12.6B (up 10.2% year on year) and net income of $4.4B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $3.8B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VRTXVertex Pharmaceuticals IncorporatedFollow VRTX — free
—
Price chart with a free account
- Market cap
- 132.8B
- P/E TTM
- 30.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.14 | 1.41 | 1.53 | 1.21 | 0.58 | 1.03 | 1.70 | 2.49 | 3.05 | 4.16 | 6.21 | 7.57 | 8.93 | 9.87 | 11.02 | 12.00 | 12.59 | |
| Gross profit | — | 1.35 | 1.29 | 1.12 | 0.54 | 0.92 | 1.50 | 2.22 | 2.64 | 3.62 | 5.47 | 6.67 | 7.85 | 8.61 | 9.49 | 10.35 | 10.82 | |
| Research & development | 0.64 | 0.71 | 0.77 | 0.88 | 0.86 | 1.00 | 1.05 | 1.32 | 1.42 | 1.75 | 1.83 | 3.05 | 2.54 | 3.16 | 3.63 | 3.91 | 3.91 | |
| Operating income | -0.70 | 0.11 | 0.05 | -0.61 | -0.69 | -0.47 | 0.01 | 0.12 | 0.64 | 1.20 | 2.86 | 2.78 | 4.31 | 3.83 | -0.23 | 4.17 | 4.78 | |
| Pre-tax income | -0.75 | 0.06 | 0.03 | -0.63 | -0.73 | -0.56 | -0.07 | -0.02 | 0.60 | 1.39 | 3.12 | 2.73 | 4.23 | 4.38 | 0.25 | 4.64 | 5.27 | |
| Income tax | 0.00 | 0.02 | -0.00 | -0.12 | 0.01 | 0.03 | 0.02 | -0.11 | -1.49 | 0.22 | 0.41 | 0.39 | 0.91 | 0.76 | 0.78 | 0.69 | 0.87 | |
| Net income | -0.75 | 0.03 | -0.11 | -0.45 | -0.74 | -0.56 | -0.11 | 0.26 | 2.10 | 1.18 | 2.71 | 2.34 | 3.32 | 3.62 | -0.54 | 3.95 | 4.41 | |
| Diluted EPS ($) | -3.77 | 0.14 | -0.50 | -1.98 | -3.14 | -2.31 | -0.46 | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 17.17 | |
| Diluted shares (bn) | 0.200 | 0.209 | 0.215 | 0.225 | 0.235 | 0.241 | 0.245 | 0.253 | 0.259 | 0.261 | 0.263 | 0.260 | 0.259 | 0.261 | 0.258 | 0.258 | — |
USD billions · SEC XBRL
Vertex Pharmaceuticals Incorporated — questions
- What is Vertex Pharmaceuticals Incorporated's revenue?
- $12.6B over the twelve months to 2026-06-30, up 10.2% year on year, from its 10-Q and 10-K filings.
- What is Vertex Pharmaceuticals Incorporated's net income?
- $4.4B over the twelve months to 2026-06-30.
- What is Vertex Pharmaceuticals Incorporated's free cash flow?
- $3.8B over the twelve months to 2026-06-30.
- What are Vertex Pharmaceuticals Incorporated's diluted earnings per share?
- $17.17 over the twelve months to 2026-06-30.
Every figure on this page comes from Vertex Pharmaceuticals Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.